Ionis Pharmaceuticals announced positive results from Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia patients.
Olezarsen showed significant reductions in fasting triglycerides and acute pancreatitis events.
Results suggest potential paradigm shift in sHTG treatment.
Statistically Significant Reductions
Olezarsen achieved up to 72% reduction in fasting triglycerides and 85% reduction in pancreatitis events.
First Treatment of its Kind
Olezarsen is the first therapy for sHTG to significantly reduce acute pancreatitis events.
Favorable Safety Profile
Olezarsen demonstrated favorable safety and tolerability in the studies.
sNDA Submission Plans
Ionis plans to submit a supplemental new drug application by end of the year.
- The studies showed groundbreaking results with significant reductions in key health indicators for sHTG patients.
- Olezarsen's potential to change the treatment paradigm for severe hypertriglyceridemia is highlighted by the data.
The CORE and CORE2 studies present promising outcomes for Olezarsen as a potential transformative therapy for severe hypertriglyceridemia.